CELEX: 62015CA0629
Language: en
Date: 2017-06-28 00:00:00
Title: Joined Cases C-629/15 P and C-630/15 P: Judgment of the Court (Eighth Chamber) of 28 June 2017 — Novartis Europharm Ltd v European Commission, Teva Pharma BV (C-629/15 P), Hospira UK Ltd (C-630/15 P) (Appeal — Medicinal products for human use — Marketing authorisation — Regulation (EEC) No 2309/93 — Centralised procedure at European Union level — Development of a medicinal product that was the subject of a marketing authorisation for other therapeutic indications — Separate marketing authorisation and new trade name — Directive 2001/83/EC — Second subparagraph of Article 6(1) and Article 10(1) — Concept of a ‘global marketing authorisation’ — Regulatory data protection period)

28.8.2017   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 283/4
            
         Judgment of the Court (Eighth Chamber) of 28 June 2017 — Novartis Europharm Ltd v European Commission, Teva Pharma BV (C-629/15 P), Hospira UK Ltd (C-630/15 P)
   (Joined Cases C-629/15 P and C-630/15 P) (1)
   
   ((Appeal - Medicinal products for human use - Marketing authorisation - Regulation (EEC) No 2309/93 - Centralised procedure at European Union level - Development of a medicinal product that was the subject of a marketing authorisation for other therapeutic indications - Separate marketing authorisation and new trade name - Directive 2001/83/EC - Second subparagraph of Article 6(1) and Article 10(1) - Concept of a ‘global marketing authorisation’ - Regulatory data protection period))
   (2017/C 283/05)
   Language of the case: English
   
      Parties
   
   
      Appellant: Novartis Europharm Ltd (represented by: C. Schoonderbeek, advocaat)
   
      Other parties to the proceedings: European Commission (represented by: K. Mifsud-Bonnici, A. Sipos and M. Šimerdová, acting as Agents), Teva Pharma BV (represented by: K. Bacon QC, instructed by C. Firth, Solicitor) (C-629/15 P), Hospira UK Ltd (represented by: J. Stratford QC, instructed by E. Vickers and N. Stoate, Solicitors) (C-630/15 P)
   
      Operative part of the judgment
   
   The Court:
   
               1.
            
            
               Dismisses the appeals in Cases C-629/15 P and C-630/15 P;
            
         
               2.
            
            
               Orders Novartis Europharm Ltd to bear its own costs and to pay those incurred by the European Commission, by Teva Pharma BV and by Hospira UK Ltd in Cases C-629/15 P and C-630/15 P.
            
         
      (1)  OJ C 38, 1.2.2016.